PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
In a placebo-controlled, double-blind, randomized clinical trial of 199 healthy participants, larch arabinogalactan tended to decrease the incidence of common colds [PMID:23339578].
In mice with DSS-induced colitis, larch arabinogalactan significantly alleviated symptoms, regulated inflammatory cytokines, and improved intestinal barrier function by promoting probiotics like Bacteroides thetaiotaomicron [PMID:42007799, PMID:41239997].
Supplementation (50 mg/kg/day) in a rat model of ischemia-reperfusion significantly reduced infarct size [PMID:28622474].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 11056416 (2000) — Larch arabinogalactan. · Alternative medicine review : a journal of clinical therapeutic
- 2.PMID: 24726529 (2014) — Interaction of arabinogalactan with mucins. · International journal of biological macromolecules
- 3.PMID: 10231609 (1999) — Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide. · Alternative medicine review : a journal of clinical therapeutic
- 4.PMID: 27073407 (2016) — Does larch arabinogalactan enhance immune function? A review of mechanistic and clinical trials. · Nutrition & metabolism
- 5.PMID: 12433485 (2002) — Morphology of Western larch arabinogalactan.